Vectors derived from the human immunodeficiency virus, HIV-1

Frontiers in Bioscience

Volumn 8, Issue , 2003, Pages

  Barker, Edward ^a   Planelles, Vicente ^b,c  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Gene Therapy; HIV, Review; Integration; Lentivirus Vectors; Non Dividing Cells; Packaging Construct; Pseudotype; Transfer Construct; VSV

Indexed keywords

B7 ANTIGEN; COMPLEMENTARY RNA; GAG PROTEIN; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOMODULATING AGENT; POL PROTEIN; REV PROTEIN; RIBOZYME; TRANSACTIVATOR PROTEIN; TRANSMEMBRANE CONDUCTANCE REGULATOR; VIRUS ENVELOPE PROTEIN; VIRUS PROTEIN;

CYSTIC FIBROSIS; DNA INTEGRATION; DRUG DELIVERY SYSTEM; FELINE IMMUNODEFICIENCY VIRUS; GENE DELETION; GENE EXPRESSION; GENE INSERTION; GENE TARGETING; GENE THERAPY; GENE TRANSFER; GENETIC TRANSCRIPTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; LENTIVIRUS VECTOR; MULTIGENE FAMILY; NONHUMAN; PARKINSON DISEASE; PROTEIN SYNTHESIS; REVERSE TRANSCRIPTION; REVIEW; RNA SPLICING; SIMIAN IMMUNODEFICIENCY VIRUS; TARGET CELL; VIRION; VIRUS ADSORPTION; VIRUS ENVELOPE; VIRUS GENOME; VIRUS REPLICATION; VIRUS VECTOR; ANIMAL; GENE VECTOR; GENETICS;

FELIDAE; FELINE IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; INSERTION SEQUENCES; LENTIVIRUS; SIMIAE; SIMIAN IMMUNODEFICIENCY VIRUS;

ANIMALS; GENETIC VECTORS; HIV-1; HUMANS;

EID: 3042603743     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: None     Document Type: Review

References (185)

1. Dranoff G: Cancer gene therapy: connecting basic research with clinical inquiry. J Clin Oncol 16, 2548-2556 (1998)
2. Blomer U, L. Naldini, I.M. Verma, D. Trono & F.H. Gage: Applications of gene therapy to the CNS. Hum Mol Genet 5 Spec No, 1397-1404 (1996)
3. Bunnell B.A. & R.A. Morgan: Gene therapy for infectious diseases. Clin Microbiol Rev 11, 42-56 (1998)
4. Karlsson S: Treatment of genetic defects in hematopoietic cell function by gene transfer. Blood 78, 2481-2492 (1991)
5. Whartenby K.A, G.N. Abraham, P.A. Calabresi, C.N. Abboud, P. Calabresi, A. Marrogi & S.M. Freeman: Gene-modified cells for the treatment of cancer. Pharmacol Ther 66, 175-190 (1995)
6. Mitchell P: Vector problems still thwart gene-therapy promise. Lancet 351, 346 (1998)
7. Lewis P.F. & M. Emerman: Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus. J Virol 68, 510-516 (1994)
8. Amado R.G. & I.S. Chen: Lentiviral vectors - the promise of gene therapy within reach? Science 285, 674-676 (1999)
9. Heinzinger N.K, M.I. Bukinsky, S.A. Haggerty, A.M. Ragland, V. Kewalramani, M.A. Lee, H.E. Gendelman, L. Ratner, M. Stevenson & M. Emerman: The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells. Proc Natl Acad Sci U S A 91, 7311-7315 (1994)
10. Bukrinsky M.I. & O.K. Haffar: HIV-1 nuclear import: in search of a leader. Front Biosci 2, 578-587 (1997)
11. J Coffin, S Hughes & H Varmus: Retroviruses. Cold Spring Harbor Laboratory Press, NY (1997)
12. Hermens W.T. & J. Verhaagen: Viral vectors, tools for gene transfer in the nervous system. Prog Neurobiol 55, 399-432 (1998)
13. Hoggan M.D, N.R. Blacklow & W.P. Rowe: Studies of small DNA viruses found in various adenovirus preparations: physical, biological, and immunological characteristics. Proc Natl Acad Sci U S A 55, 1467-1474 (1966)
14. Harel J, E. Rassart & P. Jolicoeur: Cell cycle dependence of synthesis of unintegrated viral DNA in mouse cells newly infected with murine leukemia virus. Virology 110, 202-207 (1981)
15. N Teich & T Dexter: Effects of murine leukemia virus infection on differentiation of hematopoietic cells in vitro. In: Differentiation of normal and neoplastic hematopoietic cells. Eds: Clarkson B, Marks P, Till J. Cold Spring Harbor Laboratory Press, NY (1982)
16. J Coffin: Retroviridae: The viruses and their replication. Lippincott-Raven Publishers, PA (1996)
17. Narayan O, J.S. Wolinsky, J.E. Clements, J.D. Strandberg, D.E. Griffin & L.C. Cork: Slow virus replication: the role of macrophages in the persistence and expression of visna viruses of sheep and goats. J Gen Virol 59, 345-356 (1982)
18. Trowbridge R.S, J. Lehmann, C. Torchio & P. Brophy: Visna virus synthesized in absence of host-cell division and DNA synthesis. Microbios 29, 71-80 (1980)
19. J Sanjay V, E Stephens & O Narayan: Lentiviruses. In: Fields Virology. Eds: Fields B, Knipe D, Howley P. Lippincott-Raven Publishers, PA (1996)
20. Frankel A.D. & J.A. Young: HIV-1: fifteen proteins and an RNA. Annu Rev Biochem 67, 1-25 (1998)
21. Gallay P, V. Stitt, C. Mundy, M. Oettinger & D. Trono: Role of the karyopherin pathway in human immunodeficiency virus type 1 nuclear import. J Virol 70, 1027-1032 (1996)
22. Gallay P, S. Swingler, J. Song, F. Bushman & D. Trono: HIV nuclear import is governed by the phosphotyrosine-mediated binding of matrix to the core domain of integrase. Cell 83, 569-576 (1995)
23. Haffar O.K, S. Popov, L. Dubrovsky, I. Agostini, H. Tang, T. Pushkarsky, S.G. Nadler & M. Bukrinsky: Two nuclear localization signals in the HIV-1 matrix protein regulate nuclear import of the HIV-1 pre-integration complex. J Mol Biol 299, 359-368. (2000)
24. Huang M, J.M. Orenstein, M.A. Martin & E.O. Freed: p6Gag is required for particle production from full-length human immunodeficiency virus type 1 molecular clones expressing protease. J Virol 69, 6810-6818. (1995)
25. Yu X.F, Z. Matsuda, Q.C. Yu, T.H. Lee & M. Essex: Role of the C terminus Gag protein in human immunodeficiency virus type 1 virion assembly and maturation. J Gen Virol 76, 3171-3179. (1995)
26. Bachand F, X.J. Yao, M. Hrimech, N. Rougeau & E.A. Cohen: Incorporation of Vpr into human immunodeficiency virus type 1 requires a direct interaction with the p6 domain of the p55 gag precursor. J Biol Chem 274, 9083-9091. (1999)
27. Nakamura T, T. Masuda, T. Goto, K. Sano, M. Nakai & S. Harada: Lack of infectivity of HIV-1 integrase zinc finger-like domain mutant with morphologically normal maturation. Biochem Biophys Res Commun 239, 715-722. (1997)
28. Wei P, M.E. Garber, S.M. Fang, W.H. Fischer & K.A. Jones: A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA. Cell 92, 451-462 (1998)
29. Shibata R, H. Sakai, K. Ogawa, A. Ishimoto & A. Adachi: Comparative studies on tat mutants of three primate lentiviruses. Arch Virol 114, 243-250 (1990)
30. Berchtold S, U. Hornung & C. Aepinus: The activation domain of simian immunodeficiency virus SIV mac239 Rev protein is structurally and functionally analogous to the HIV-1 Rev activation domain. Virology 211, 285-289 (1995)
31. Dillon PJ, P. Nelbock, A. Perkins & C.A. Rosen: Function of the human immunodeficiency virus types 1 and 2 Rev proteins is dependent on their ability to interact with a structured region present in env gene mRNA. J Virol 64, 4428-4437 (1990)
32. Le S.Y, M.H. Malim, B.R. Cullen & J.V. Maizel: A highly conserved RNA folding region coincident with the Rev response element of primate immunodeficiency viruses. Nucleic Acids Res 18, 1613-1623 (1990)
33. Olsen H.S, S. Beidas, P. Dillon, C.A. Rosen & A.W. Cochrane: Mutational analysis of the HIV-1 Rev protein and its target sequence, the Rev responsive element. J Acquir Immune Defic Syndr 4, 558-567 (1991)
34. Viglianti G.A, P.L. Sharma & J.I. Mullins: Simian immunodeficiency virus displays complex patterns of RNA splicing. J Virol 64, 4207-4216 (1990)
35. Fischer U, V.W. Pollard, R. Luhrmann, M. Teufel, M.W. Michael, G. Dreyfuss & M.H. Malim: Rev-mediated nuclear export of RNA is dominant over nuclear retention and is coupled to the Ran-GTPase cycle. Nucleic Acids Res 27, 4128-4134. (1999)
36. P Luciw: Human immunodeficiency viruses and their replication. In: Fields Virology. Eds: Fields B, Knippe, D, Howley P, Lippincott-Raven Press, PA (1996)
37. Bour S. & K. Strebel: HIV accessory proteins: multifunctional components of a complex system. Adv Pharmacol 48, 75-120 (2000)
38. Roshal M, Y. Zhu & V. Planelles: Apoptosis in AIDS. Apoptosis 6, 103-116 (2001)
39. Zaitseva M, A. Blauvelt, S. Lee, C.K. Lapham, V. Klaus-Kovtun, H. Mostowski, J. Manischewitz & H. Golding: Expression and function of CCR5 and CXCR4 on human Langerhans cells and macrophages: implications for HIV primary infection. Nat Med 3, 1369-1375 (1997)
40. Lowe J, K.A. MacLennan, D.G. Powe, J.D. Pound & J.B. Palmer: Microglial cells in human brain have phenotypic characteristics related to possible function as dendritic antigen presenting cells. J Pathol 159, 143-149 (1989)
41. Bell J.E: The neuropathology of adult HIV infection. Rev Neurol 154, 816-829 (1998)
42. Albright A.V, J.T. Shieh, T. Itoh, B. Lee, D. Pleasure, M.J. O'Connor, R.W. Doms & F. Gonzalez-Scarano: Microglia express CCR5, CXCR4, and CCR3, but of these, CCR5 is the principal coreceptor for human immunodeficiency virus type 1 dementia isolates. J Virol 73, 205-213 (1999)
43. Maddon P.J, J.S. McDougal, P.R. Clapham, A.G. Dalgleish, S. Jamal, R.A. Weiss & R. Axel: HIV infection does not require endocytosis of its receptor, CD4. Cell 54, 865-874 (1988)
44. Schnitzer T.J, R.A. Weiss & J. Zavada: Pseudotypes of vesicular stomatitis virus with the envelope properties of mammalian and primate retroviruses. J Virol 23, 449-454 (1977)
45. Witte O.N. & D. Baltimore: Mechanism of formation of pseudotypes between vesicular stomatitis virus and murine leukemia virus. Cell 11, 505-511 (1977)
46. Kang C.Y. & P. Lambright: Pseudotypes of vesicular stomatitis virus with the mixed coat of reticuloendotheliosis virus and vesicular stomatitis virus. J Virol 21, 1252-1255 (1977)
47. Burns J.C, T. Friedmann, W. Driever, M. Burrascano & J.K. Yee: Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc Natl Acad Sci U S A 90, 8033-8037 (1993)
48. Aiken C: Pseudotyping human immunodeficiency virus type 1 (HIV-1) by the glycoprotein of vesicular stomatitis virus targets HIV-1 entry to an endocytic pathway and suppresses both the requirement for Nef and the sensitivity to cyclosporin A. J Virol 71, 5871-5877 (1997)
49. Akkina R.K, R.M. Walton, M.L. Chen, Q.X. Li, V. Flanelles & I.S. Chen: High-efficiency gene transfer into CD34+ cells with a human immunodeficiency virus type 1-based retro viral vector pseudotyped with vesicular stomatitis virus envelope glycoprotein G. J Virol 70, 2581-2585 (1996)
50. Mastromarino P, C. Conti, P. Goldoni, B. Hauttecoeur & N. Orsi: Characterization of membrane components of the erythrocyte involved in vesicular stomatitis virus attachment and fusion at acidic pH. J Gen Virol 68, 2359-2369 (1987)
51. DePolo N.J, J.D. Reed, P.L. Sheridan, K. Townsend, S.L. Sauter, D.J. Jolly & T.W. Dubensky, Jr: VSV-G pseudotyped lentiviral vector particles produced in human cells are inactivated by human serum. Mol Ther 2, 218-222 (2000)
52. Sakai H, M. Kawamura, J. Sakuragi, S. Sakuragi, R. Shibata, A. Ishimoto, N. Ono, S. Ueda & A. Adachi: Integration is essential for efficient gene expression of human immunodeficiency virus type 1. J Virol 67, 1169-1174 (1993)
53. Masuda T, V. Flanelles, P. Krogstad & I. Chen: Genetic analysis of human immunodeficiency virus type 1 integrase and the U3 att site: unusual phenotype of mutants in the zinc finger-like domain. J Virol 69, 6687-6696 (1995)
54. Withers-Ward E.S, Y. Kitamura, J.P. Barnes & J.M. Coffin: Distribution of targets for avian retrovirus DNA integration in vivo. Genes Dev 8, 1473-1487 (1994)
55. Carteau S, C. Hoffmann & F. Bushman: Chromosome structure and human immunodeficiency virus type 1 cDNA integration: centromeric alphoid repeats are a disfavored target. J Virol 72, 4005-4014 (1998)
56. Naldini L, U. Blomer, P. Gallay, D. Ory, R. Mulligan, F.H. Gage, I.M. Verma & D. Trono: In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272, 263-267 (1996)
57. White S.M, M. Renda, N.Y. Nam, E. Klimatcheva, Y. Zhu, J. Fisk, M. Halterman, B.J. Rimel, H. Federoff, S. Pandya, J.D. Rosenblatt & V. Planelles: Lentivirus vectors using human and simian immunodeficiency virus elements. J Virol 73, 2832-2840 (1999)
58. Hill C.L, P.D. Bieniasz & M.O. McClure: Properties of human foamy virus relevant to its development as a vector for gene therapy. J Gen Virol 80, 2003-2009 (1999)
59. Wu M. & A. Mergia: Packaging cell lines for simian foamy virus type 1 vectors. J Virol 73, 4498-4501 (1999)
60. Trobridge G.D. & D.W. Russell: Helper-free foamy virus vectors. Hum Gene Ther 9, 2517-2525 (1998)
61. Nestler U, M. Heinkelein, M. Lucke, J. Meixensberger, W. Scheurlen, A. Kretschmer & A. Rethwilm: Foamy virus vectors for suicide gene therapy. Gene Ther 4, 1270-1277 (1997)
62. Bieniasz P.D, O. Erlwein, A. Aguzzi, A. Rethwilm & M.O. McClure: Gene transfer using replication-defective human foamy virus vectors. Virology 235, 65-72 (1997)
63. Hirata R.K, A.D. Miller, R.G. Andrews & D.W. Russell: Transduction of hematopoietic cells by foamy virus vectors. Blood 88, 3654-3661 (1996)
64. Russell D.W. & A.D. Miller: Foamy virus vectors. J Virol 70, 217-222 (1996)
65. Gallay P, T. Hope, D. Chin & D. Trono: HIV-1 infection of nondividing cells through the recognition of integrase by the importin/karyopherin pathway. Proc Natl Acad Sci U S A 94, 9825-9830 (1997)
66. Zennou V, C. Petit, D. Guetard, U. Nerhbass, L. Montagnier & P. Chameau: HIV-1 genome nuclear import is mediated by a central DNA flap. Cell 101, 173-185 (2000)
67. Gorlich D. & I.W. Mattaj: Nucleocytoplasmic transport. Science 271, 1513-1518 (1996)
68. Popov S, M. Rexach, L. Ratner, G. Blobel & M. Bukrinsky: Viral protein R regulates docking of the HIV-1 preintegration complex to the nuclear pore complex. J Biol Chem 273, 13347-13352 (1998)
69. Chameau P. & F. Clavel: A single-stranded gap in human immunodeficiency virus unintegrated linear DNA defined by a central copy of the polypurine tract. J Virol 65, 2415-2421 (1991)
70. Follenzi A, L.E. Ailles, S. Bakovic, M. Geuna & L. Naldini: Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HTV-1 pol sequences. Nat Genet 25, 217-222 (2000)
71. Sirven A, F. Pflumio, V. Zennou, M. Titeux, W. Vainchenker, L. Coulombel, A. Dubart-Kupperschmitt & P. Chameau: The human immunodeficiency virus type-1 central DNA flap is a crucial determinant for lentiviral vector nuclear import and gene transduction of human hematopoietic stem cells. Blood 96, 4103-4110. (2000)
72. Page K.A, N.R. Landau & D.R. Littman: Construction and use of a human immunodeficiency virus vector for analysis of virus infectivity. J Virol 64, 5270-5276 (1990)
73. Landau N.R, K.A. Page & D.R. Littman: Pseudotyping with human T-cell leukemia virus type I broadens the human immunodeficiency virus host range. J Virol 65, 162-169 (1991)
74. Camerini D, V. Planelles & I. Chen: CD26 antigen and HIV fusion? Science 264, 1160-1161 (1994)
75. Planelles V, F. Bachelerie, J.B.M. Jowett, A. Haislip, Y. Xie, P. Banooni, T. Masuda & I.S.Y. Chen: Fate of the human immunodeficiency virus type 1 provirus in infected cells: a role for vpr. J Virol 69, 5883-5889 (1995)
76. Buchschacher G.L, Jr. & A.T. Panganiban: Human immunodeficiency virus vectors for inducible expression of foreign genes. J Virol 66, 2731-2739 (1992)
77. Hock R.A. & A.D. Miller: Retrovirus-mediated transfer and expression of drug resistance genes in human haematopoietic progenitor cells. Nature 320, 275-277 (1986)
78. Hogge D.E. & R.K. Humphries: Gene transfer to primary normal and malignant human hemopoietic progenitors using recombinant retroviruses. Blood 69, 611-617 (1987)
79. Parolin C, T. Dorfman, G. Palu, H. Gottlinger & J. Sodroski: Analysis in human immunodeficiency virus type 1 vectors of cis-acting sequences that affect gene transfer into human lymphocytes. J Virol 68, 3888-3895 (1994)
80. Miller N. & J. Whelan: Progress in transcriptionally targeted and regulatable vectors for genetic therapy. Hum Gene Ther 8, 803-815 (1997)
81. Purcell D.F, C.M. Broscius, E.F. Vanin, C.E. Buckler, A.W. Nienhuis & M.A. Martin: An array of murine leukemia virus-related elements is transmitted and expressed in a primate recipient of retroviral gene transfer. J Virol 70, 887-897 (1996)
82. Donahue R.E, S.W. Kessler, D. Bodine, K. McDonagh, C. Dunbar, S. Goodman, B. Agricola, E. Byrne, M. Raffeld, R. Moen, J. Bacher, K.M. Zsebo & A.W. Nienhuis: Helper virus induced T cell lymphoma in nonhuman primates after retroviral mediated gene transfer. J Exp Med 176, 1125-1135 (1992)
83. Vanin E.F, M. Kaloss, C. Broscius & A.W. Nienhuis: Characterization of replication-competent retroviruses from nonhuman primates with virus-induced T-cell lymphomas and observations regarding the mechanism of oncogenesis. J Virol 68, 4241-4250 (1994)
84. Markowitz D, S. Goff & A. Bank: Construction and use of a safe and efficient amphotropic packaging cell line. Virology 167, 400-406 (1988)
85. Chong H. & R.G. Vile: Replication-competent retrovirus produced by a 'split-function' third generation amphotropic packaging cell line. Gene Ther 3, 624-629 (1996)
86. Otto E, A. Jones-Trower, E.F. Vanin, K. Stambaugh, S.N. Mueller, W.F. Anderson & G.J. McGarrity: Characterization of a replication-competent retrovirus resulting from recombination of packaging and vector sequences. Hum Gene Ther 5, 567-575 (1994)
87. Dougherty J.P. & H.M. Temin: A promoterless retroviral vector indicates that there are sequences in U3 required for 3′ RNA processing. Proc Natl Acad Sci U S A 84, 1197-1201 (1987)
88. Yu S.F, T. von Ruden, P.W. Kantoff, C. Garber, M. Seiberg, U. Ruther, W.F. Anderson, E.F. Wagner & E. Gilboa: Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells. Proc Natl Acad Sci U S A 83, 3194-3198 (1986)
89. A Miller: Development and application of retroviral vectors. In: Retroviruses. Eds: Coffin J, Hughes S, Varmus H. Cold Spring Harbor Laboratory Press, NY (1997)
90. Miyoshi H, U. Blomer, M. Takahashi, F.H. Gage & I.M. Verma: Development of a self-inactivating lentivirus vector. J Virol 72, 8150-8157 (1998)
91. Iwakuma T, Y. Cui & L.J. Chang: Self-inactivating lentiviral vectors with U3 and U5 modifications. Virology 261, 120-132 (1999)
92. Zufferey R, T. Dull, R.J. Mandel, A. Bukovsky, D. Quiroz, L. Naldini & D. Trono: Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol 72, 9873-9880 (1998)
93. Xu K, H. Ma, T.J. McCown, I.M. Verma & T. Kafri: Generation of a stable cell line producing high-liter self-inactivating lentiviral vectors. Mol Ther 3, 97-104. (2001)
94. Urlinger S, U. Baron, M. Thellmann, M.T. Hasan, H. Bujard & W. Hillen: Exploring the sequence space for tetracycline-dependent transcriptional activators: novel mutations yield expanded range and sensitivity. Proc Natl Acad Sci U S A 91, 7963-7968 (2000)
95. Freundlieb S, C. Schirra-Muller & H. Bujard: A tetracycline controlled activation/repression system with increased potential for gene transfer into mammalian cells. J Gene Med 1, 4-12 (1999)
96. Bujard H: Controlling genes with tetracyclines. J Gene Med 1, 372-374 (1999)
97. Kafri T, H. van Praag, F.H. Gage & I.M. Verma: Lenti viral vectors: regulated gene expression. Mol Ther 1, 516-521 (2000)
98. Choi T, M. Huang, C. Gorman & R. Jaenisch: A generic intron increases gene expression in transgenic mice. Mol Cell Biol 11, 3070-3074 (1991)
99. Zufferey R, J.E. Donello, D. Trono & T.J. Hope: Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. J Virol 73, 2886-2892 (1999)
100. Sirven A, E. Ravet, P. Charneau, V. Zennou, L. Coulombel, D. Guetard, F. Pflumio & A. Dubart-Kupperschmitt: Enhanced transgene expression in cord blood cd34(+)-derived hematopoietic cells, including developing t cells and nod/scid mouse repopulating cells, following transduction with modified trip lentiviral vectors. Mol Ther 3, 438-448. (2001)
101. Salmon P, V. Kindler, O. Ducrey, B. Chapuis, R.H. Zubler & D. Trono: High-level transgene expression in human hematopoietic progenitors and differentiated blood lineages after transduction with improved lentiviral vectors. Blood 96, 3392-3398. (2000)
102. Osborne C.S, P. Pasceri, R. Singal, T. Sukonnik, G.D. Ginder & J. Ellis: Amelioration of retroviral vector silencing in locus control region beta-globin-transgenic mice and transduced F9 embryonic cells. J Virol 73, 5490-5496 (1999)
103. Pannell D, C.S. Osborne, S. Yao, T. Sukonnik, P. Pasceri, A. Karaiskakis, M. Okano, E. Li, H.D. Lipshitz & J. Ellis: Retrovirus vector silencing is de novo methylase independent and marked by a repressive histone code. Embo J 19, 5884-5894 (2000)
104. Reiser J: Production and concentration of pseudotyped HIV-1-based gene transfer vectors. Gene Ther 7, 910-913 (2000)
105. Chu T.H. & R. Dornburg: Toward highly efficient cell-type-specific gene transfer with retroviral vectors displaying single-chain antibodies. J Virol 71, 720-725 (1997)
106. Martin F, J. Kupsch, Y. Takeuchi, S. Russell, F.L. Cosset & M. Collins: Retroviral vector targeting to melanoma cells by single-chain antibody incorporation in envelope. Hum Gene Ther 9, 737-746 (1998)
107. Wu B.W, J. Lu, T.K. Gallaher, W.F. Anderson & P.M. Cannon: Identification of regions in the Moloney murine leukemia virus SU protein that tolerate the insertion of an integrin-binding peptide. Virology 269, 7-17 (2000)
108. Nguyen T.H, J.C. Pages, D. Farge, P. Briand & A. Weber: Amphotropic retroviral vectors displaying hepatocyte growth factor-envelope fusion proteins improve transduction efficiency of primary hepatocytes. Hum Gene Ther 9, 2469-2479 (1998)
109. Kobinger G.P, D.J. Weiner, Q.C. Yu & J.M. Wilson: Filovirus-pseudotyped lentiviral vector can efficiently and stably transduce airway epithelia in vivo. Nat Biotechnol 19, 225-230. (2001)
110. Ito H, S. Watanabe, A. Takada & Y. Kawaoka: Ebola virus glycoprotein: proteolytic processing, acylation, cell tropism, and detection of neutralizing antibodies. J Virol 75, 1576-1580. (2001)
111. Zufferey R, D. Nagy, R.J. Mandel, L. Naldini & D. Trono: Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 15, 871-875 (1997)
112. Uchida N, R.E. Sutton, A.M. Friera, D. He, M.J. Reitsma, W.C. Chang, G. Veres, R. Scollay & I.L. Weissman: HIV, but not murine leukemia virus, vectors mediate high efficiency gene transfer into freshly isolated GO/G1 human hematopoietic stem cells. Proc Natl Acad Sci U S A 95, 11939-11944 (1998)
113. Mochizuki H, J.P. Schwartz, K. Tanaka, R.O. Brady & J. Reiser: High-titer human immunodeficiency virus type 1-based vector systems for gene delivery into nondividing cells. J Virol 72, 8873-8883 (1998)
114. Kim V.N, K. Mitrophanous, S.M. Kingsman & A.J. Kingsman: Minimal requirement for a lentivirus vector based on human immunodeficiency virus type 1. J Virol 72, 811-816 (1998)
115. Pandya S, K. Boris-Lawrie, N.J. Leung, R.K. Akkina & V. Planelies: Development of a Rev-Independent, minimal simian immunodeficiency virus-derived vector system. Hum Gen Ther 12, 847-857 (2001)
116. Dull T, R. Zufferey, M. Kelly, R.J. Mandel, M. Nguyen, D. Trono & L. Naldini: A third-generation lentivirus vector with a conditional packaging system J Virol 72, 8463-8471 (1998)
117. Schnell T, P. Foley, M. Wirth, J. Munch & K. Uberla: Development of a self-inactivating, minimal lentivirus vector based on simian immunodeficiency virus. Hum Gene Ther 11, 439-447 (2000)
118. Kotsopoulou E, V.N. Kim, A.J. Kingsman, S.M. Kingsman & K.A. Mitrophanous: A Rev-independent human immunodeficiency virus type 1 (HIV-1)-based vector that exploits a codon-optimized HIV-1 gag-pol gene. J Virol 74, 4839-4852 (2000)
119. Wu X, J.K. Wakefield, H. Liu, H. Xiao, R. Kralovics, J.T. Prchal & J.C. Kappes: Development of a novel trans-lentiviral vector that affords predictable safety. Mol Ther 2, 47-55 (2000)
120. Gasmi M, J. Glynn, M.J. Jin, D.J. Jolly, J.K. Yee & S.T. Chen: Requirements for efficient production and transduction of human immunodeficiency virus type 1-based vectors. J Virol 73, 1828-1834 (1999)
121. Boris-Lawrie K. & H.M. Temin: Genetically simpler bovine leukemia virus derivatives can replicate independently of Tax and Rex. J Virol 69, 1920-1924 (1995)
122. Butsch M, S. Hull, Y. Wang, T.M. Roberts & K. Boris-Lawrie: The 5′ RNA terminus of spleen necrosis virus contains a novel posttranscriptional control element that facilitates human immunodeficiency virus Rev/RRE-independent Gag production. J Virol 73, 4847-4855 (1999)
123. Roberts T.M. & K. Boris-Lawrie: The 5′ RNA terminus of spleen necrosis virus stimulates translation of nonviral mRNA. J Virol 74, 8111-8118 (2000)
124. Pacchia A.L, M.E. Adelson, M. Kaul, Y. Ron & J.P. Dougherty: An inducible packaging cell system for safe, efficient lentiviral vector production in the absence of HIV-1 accessory proteins. Virology 282, 77-86. (2001)
125. Rizvi T.A. & A.T. Panganiban: Simian immunodeficiency virus RNA is efficiently encapsidated by human immunodeficiency virus type 1 particles. J Virol 67, 2681-2688 (1993)
126. Embretson J.E. & H.M. Temin: Lack of competition results in efficient packaging of heterologous murine retroviral RNAs and reticuloendotheliosis virus encapsidation- minus RNAs by the reticuloendotheliosis virus helper cell line. J Virol 61, 2675-2683 (1987)
127. Corbeau P, G. Kraus & F. Wong-Staal: Transduction of human macrophages using a stable HIV-1/HIV-2-derived gene delivery system. Gene Ther 5, 99-104 (1998)
128. Kaye J.F. & A.M. Lever: Nonreciprocal packaging of human immunodeficiency virus type 1 and type 2 RNA: a possible role for the p2 domain of Gag in RNA encapsidation. J Virol 72, 5877-5885 (1998)
129. Browning M.T, R.D. Schmidt, K.A. Lew & T.A. Rizvi: Primate and feline lentivirus vector RNA packaging and propagation by heterologous lentivirus virions. J Virol 75, 5129-5140. (2001)
130. Corbeau P, G. Kraus & F. Wong-Staal: Efficient gene transfer by a human immunodeficiency virus type 1 (HIV-1)-derived vector utilizing a stable HIV packaging cell line. Proc Natl Acad Sci U S A 93, 14070-14075 (1996)
131. Srinivasakumar N, N. Chazal, C. Helga-Maria, S. Prasad, M.L. Hammarskjold & D. Rekosh: The effect of viral regulatory protein expression on gene delivery by human immunodeficiency virus type 1 vectors produced in stable packaging cell lines. J Virol 71, 5841-5848 (1997)
132. Yu H, A.B. Rabson, M. Kaul, Y. Ron & J.P. Dougherty: Inducible human immunodeficiency virus type 1 packaging cell lines. J Virol 70, 4530-4537 (1996)
133. Kaul M, H. Yu, Y. Ron & J.P. Dougherty: Regulated lentiviral packaging cell line devoid of most viral cis- acting sequences. Virology 249, 167-174 (1998)
134. Kafri T, H. van Praag, L. Ouyang, F.H. Gage & I.M. Verma: A packaging cell line for lentivirus vectors. J Virol 73, 576-584 (1999)
135. Dropulic B, M. Hermankova & P.M. Pitha: A conditionally replicating HIV-1 vector interferes with wild-type HIV-1 replication and spread. Proc Natl Acad Sci U S A 93, 11103-11108 (1996)
136. Mautino M.R. & R.A. Morgan: Potent inhibition of human immunodeficiency virus type 1 replication by conditionally replicating human immunodeficiency virus-based lentiviral vectors expressing envelope antisense mRNA. Hum Gene Ther 11, 2025-2037. (2000)
137. Corbeau P. & F. Wong-Staal: Anti-HIV effects of HIV vectors. Virology 243, 268-274 (1998)
138. An D.S, K. Morizono, Q.X. Li, S.H. Mao, S. Lu & I.S. Chen: An inducible human immunodeficiency virus type 1 (HIV-1) vector which effectively suppresses HIV-1 replication. J Virol 73, 7671-7677 (1999)
139. Bukovsky A.A, J.P. Song & L. Naldini: Interaction of human immunodeficiency virus-derived vectors with wild-type virus in transduced cells. J Virol 73, 7087-7092 (1999)
140. Klimatcheva E, V. Planelles, S.L. Day, F. Fulreader, M.J. Renda & J. Rosenblatt: Defective lentiviral vectors are efficiently trafficked by hiv-1 and inhibit its replication. Mol Ther 3, 928-939 (2001)
141. Volsky D.J, M. Simm, M. Shahabuddin, G. Li, W. Chao & M.J. Potash: Interference to human immunodeficiency virus type 1 infection in the absence of downmodulation of the principal virus receptor, CD4. J Virol 70, 3823-3833. (1996)
142. Hoglund S, A. Ohagen, J. Goncalves, A.T. Panganiban & D. Gabuzda: Ultrastructure of HIV-1 genomic RNA. Virology 233, 271-279 (1997)
143. Ding S.F, J. Noronha & S. Joshi: Co-packaging of sense and anti sense RNAs: a novel strategy for blocking HIV-1 replication. Nucleic Acids Res 26, 3270-3278 (1998)
144. Stripecke R, A.A. Cardoso, K.A. Pepper, D.C. Skelton, X.J. Yu, L. Mascarenhas, K.I. Weinberg, L.M. Nadler & D.B. Kohn: Lentiviral vectors for efficient delivery of CD80 and granulocyte-macrophage- colony-stimulating factor in human acute lymphoblastic leukemia and acute myeloid leukemia cells to induce antileukemic immune responses. Blood 96, 1317-1326 (2000)
145. Rees S, J. Coote, J. Stables, S. Goodson, S. Harris & M.G. Lee: Bicistronic vector for the creation of stable mammalian cell lines that predisposes all antibiotic-resistant cells to express recombinant proteia Biotechniques 20, 102-104 (1996)
146. Morgan R.A, L. Couture, O. Elroy-Stein, J. Ragheb, B. Moss & W.F. Anderson: Retroviral vectors containing putative internal ribosome entry sites: development of a polycistronic gene transfer system and applications to human gene therapy. Nucleic Acids Res 20, 1293-1299 (1992)
147. Wrzesinski S, R. Seguin, Y. Liu, S. Domville, V. Planelles, P. Massa, E. Barker, J. Antel & G. Feuer: HTLV type 1 tax transduction in microglial cells and astrocytes by lentiviral vectors. AIDS Res Hum Retroviruses 16, 1771-1776 (2000)
148. Nakajima T, K. Nakamaru, E. Ido, K. Terao, M. Hayami & M. Hasegawa: Development of novel simian immunodeficiency virus vectors carrying a dual gene expression system. Hum Gene Ther 11, 1863-1874 (2000)
149. Purvis S.F, J.W. Jacobberger, R.M. Sramkoski, A.H. Patki & M.M. Lederman: HIV type 1 Tat protein induces apoptosis and death in Jurkat cells. AIDS Res Hum Retroviruses 11, 443-450 (1995)
150. Bartz S.R. & M. Emerman: Human immunodeficiency virus type 1 Tat induces apoptosis and increases sensitivity to apoptotic signals by up-regulating FLICE/caspase-8. J Virol 73, 1956-1963 (1999)
151. Zhu Y, G. Feuer, S.L. Day, S. Wrzesinski & V. Planelles: Multigene lentiviral vectors based on differential splicing and translational control. Mol Ther 4, 375-382 (2001)
152. Goulaouic H. & S.A. Chow: Directed integration of viral DNA mediated by fusion proteins consisting of human immunodeficiency virus type 1 integrase and Escherichia coli LexA protein. J Virol 70, 37-46 (1996)
153. Holmes-Son M.L. & S.A. Chow: Integrase-LexA Fusion Proteins Incorporated into Human Immunodeficiency Virus Type 1 That Contains a Catalytically Inactive Integrase Gene Are Functional To Mediate Integration. J Virol 74, 11548-11556 (2000)
154. Bushman F: Targeting retroviral integration. Science 267, 1443-1444 (1995)
155. Bushman F.D. & M.D. Miller: Tethering human immunodeficiency virus type 1 preintegration complexes to target DNA promotes integration at nearby sites. J Virol 71, 458-464 (1997)
156. Shibagaki Y. & S.A. Chow: Central core domain of retroviral integrase is responsible for target site selection. J Biol Chem 272, 8361-8369 (1997)
157. Arya S.K, M. Zamani & P. Kundra: Human immunodeficiency virus type 2 lentivirus vectors for gene transfer: expression and potential for helper virus-free packaging. Hum Gene Ther 9, 1371-1380 (1998)
158. Poeschla E, J. Gilbert, X. Li, S. Huang, A. Ho & F. Wong-Staal: Identification of a human immunodeficiency virus type 2 (HIV-2) encapsidation determinant and transduction of nondividing human cells by HIV-2-based lentivirus vectors. J Virol 72, 6527-6536 (1998)
159. Poeschla E, P. Corbeau & F. Wong-Staal: Development of HIV vectors for anti-HIV gene therapy. Proc Natl Acad Sci U S A 93, 11395-11399 (1996)
160. Poeschla E.M, F. Wong-Staal & D.J. Looney: Efficient transduction of nondividing human cells by feline immunodeficiency virus lentiviral vectors. Nat Med 4, 354-357 (1998)
161. Johnston J.C, M. Gasmi, L.E. Lim, J.H. Elder, J.K. Yee, D.J. Jolly, K.P. Campbell, B.L. Davidson & S.L. Sauter: Minimum requirements for efficient transduction of dividing and nondividing cells by feline immunodeficiency virus vectors. J Virol 73, 4991-5000 (1999)
162. Curran M.A, S.M. Kaiser, P.L. Achacoso & G.P. Nolan: Efficient transduction of nondividing cells by optimized feline immunodeficiency virus vectors. Mol Ther 1, 31-38 (2000)
163. Wang G, V. Slepushkin, J. Zabner, S. Keshavjee, J.C. Johnston, S.L. Sauter, D.J. Jolly, T.W. Dubensky, Jr, B.L. Davidson & P.B. McCray, Jr: Feline immunodeficiency virus vectors persistently transduce nondividing airway epithelia and correct the cystic fibrosis defect J Clin Invest 104, R55-62 (1999)
164. Mselli-Lakhal L, C. Favier, M.F. Da Silva Teixeira, K. Chettab, C. Legras, C. Ronfort, G. Verdier, J.F. Mornex & Y. Chebloune: Defective RNA packaging is responsible for low transduction efficiency of CAEV-based vectors. Arch Virol 143, 681-695 (1998)
165. Berkowitz R.D, H. Ilves, I. Plavec & G. Veres: Gene transfer systems derived from Visna virus: analysis of virus production and infectivity. Virology 279, 116-129. (2001)
166. Mitrophanous K, S. Yoon, J. Rohll, D. Patil, F. Wilkes, V. Kim, S. Kingsman, A. Kingsman & N. Mazarakis: Stable gene transfer to the nervous system using a non-primate lentiviral vector. Gene Ther 6, 1808-1818 (1999)
167. Belloc C, B. Polack, I. Schwartz-Cornil, J. Brownlie & D. Levy: Bovine immunodeficiency virus: facts and questions. Vet Res 27, 395-402 (1996)
168. Wilcox G.E: Jembrana disease. Aust Vet J 75, 492-493 (1997)
169. Berkowitz R, H. Ilves, W.Y. Lin, K. Eckert, A. Coward, S. Tamaki, G. Veres & I. Plavec: Construction and molecular analysis of gene transfer
170. Goldman M.J, P.S. Lee, J.S. Yang & J.M. Wilson: Lentiviral vectors for gene therapy of cystic fibrosis. Hum Gene Ther 8, 2261-2268 (1997)
171. Chen W, X. Wu, D.N. Levasseur, H. Liu, L. Lai, J.C. Kappes & T.M. Townes: Lentiviral vector transduction of hematopoietic stem cells that mediate long-term reconstitution of lethally irradiated mice. Stem Cells 18, 352-359 (2000)
172. Miyoshi H, M. Takahashi, F.H. Gage & I.M. Verma: Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector. Proc Natl Acad Sci U S A 94, 10319-10323 (1997)
173. Schroers R, I. Sinha, H. Segall, I.G. Schmidt-Wolf, C.M. Rooney, M.K. Brenner, R.E. Sutton & S.Y. Chen: Transduction of human PBMC-derived dendritic cells and macrophages by an HIV-1-based lentiviral vector system. Mol Ther 1, 171-179 (2000)
174. Costello E, M. Munoz, E. Buetti, P.R. Meylan, H. Diggelmann & M. Thali: Gene transfer into stimulated and unstimulated T lymphocytes by HIV-1-derived lentiviral vectors. Gene Ther 7, 596-604 (2000)
175. Dyall J, J.B. Latouche, S. Schnell & M. Sadelain: Lentivirus-transduced human monocyte-derived dendritic cells efficiently stimulate antigen-specific cytotoxic T lymphocytes. Blood 91, 114-121. (2001)
176. Balboni P.G, R. Bozzini, S. Zucchini, P.C. Marconi, M.P. Grossi, A. Caputo, R. Manservigi & G. Barbanti-Brodano: Inhibition of human immunodeficiency virus reactivation from latency by a tat transdominant negative mutant. J Med Virol 41, 289-295 (1993)
177. Chadwick D.R. & A.M. Lever: Antisense RNA sequences targeting the 5′ leader packaging signal region of human immunodeficiency virus type-1 inhibits viral replication at post-transcriptional stages of the life cycle. Gene Ther 7, 1362-1368 (2000)
178. Lisziewicz J, D. Sun, A. Lisziewicz & R.C. Gallo: Antitat gene therapy: a candidate for late-stage AIDS patients. Gene Ther 2, 218-222 (1995)
179. Plavec I, M. Agarwal, K.E. Ho, M. Pineda, J. Auten, J. Baker, H. Matsuzaki, S. Escaich, M. Bonyhadi & E. Bohnlein: High transdominant RevM10 protein levels are required to inhibit HIV-1 replication in cell lines and primary T cells: implication for gene therapy of AIDS. Gene Ther 4, 128-139 (1997)
180. Smythe J.A. & G. Symonds: Gene therapeutic agents: the use of ribozymes, antisense, and RNA decoys for HIV-1 infection. Inflamm Res 44, 11-15 (1995)
181. Wang L, C. Witherington, A. King, W.L. Gerlach, A. Carr, R. Penny, D. Cooper, G. Symonds & L.Q. Sun: Preclinical characterization of an anti-tat ribozyme for therapeutic application. Hum Gene Ther 9, 1283-1291 (1998)
182. Kordower J.H, M.E. Emborg, J. Bloch, S.Y. Ma, Y. Chu, L. Leventhal, J. McBride, E.Y. Chen, S. Palfi, B.Z. Roitberg, W.D. Brown, J.E. Holden, R. Pyzalski, M.D. Taylor, P. Carvey, Z. Ling, D. Trono, P. Hantraye, N. Deglon & P. Aebischer: Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 290, 767-773. (2000)
183. Guyer M.S. & F.S. Collins: How is the Human Genome Project doing, and what have we learned so far? Proc Natl Acad Sci U S A 92, 10841-10848 (1995)
184. Cavazzana-Calvo M, S. Hacein-Bey, G. de Saint Basile, F. Gross, E. Yvon, P. Nusbaum, F. Selz, C. Hue, S. Certain, J.L. Casanova, P. Bousso, F.L. Deist & A. Fischer: Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288, 669-672 (2000)
185. Clayman G.L, D.K. Frank, P.A. Bruso & H. Goepfert: Adenovirus-mediated wild-type p53 gene transfer as a surgical adjuvant in advanced head and neck cancers. Clin Cancer Res 5, 1715-1722 (1999)